N4 Pharma plc (N4P) ORD GBP0.004
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £6.95 per trade in
a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £6.95 per trade in
a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.53p
0.55p
0.78p
£4.37 million
0.53p
0.50p
0.35p
n/a
0.00p (0.00%) Previous:
0.00p
98,943
n/a
300,000
Performance
Not available for this stock.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue (£m) | 0.01 | n/a |
| Profit before tax (£m) | (1.22) | (1.42) |
| Adjusted EPS (p): | (0.31) | (0.52) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
N4 Pharma appoints new CEO, proposes name change
24 February 2026 15:13
-
N4 Pharma reports narrower full-year operating loss
6 June 2025 12:14
-
N4 Pharma files for new UK patent
4 December 2024 14:46
-
Notice of GM and Proposed Change of Name
27 February 2026 07:00
-
CEO Appointment & Name Change Thalia Therapeutics
24 February 2026 07:00
-
Business and Operational Update
17 December 2025 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.